249 related articles for article (PubMed ID: 19435725)
1. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
Teng YK; Tekstra J; Breedveld FC; Lafeber F; Bijlsma JW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1075-7. PubMed ID: 19435725
[No Abstract] [Full Text] [Related]
2. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
3. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
Kerkeni S; Marotte H; Miossec P
Muscle Nerve; 2008 Oct; 38(4):1343-5. PubMed ID: 18816604
[No Abstract] [Full Text] [Related]
4. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
5. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
Renato GM
Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
[TBL] [Abstract][Full Text] [Related]
6. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
7. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
[TBL] [Abstract][Full Text] [Related]
8. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.
Soriano ER; Galarza-Maldonado C; Cardiel MH; Pons-Estel BA; Massardo L; Caballero-Uribe CV; Achurra-Castillo AF; Barile-Fabris LA; Chávez-Corrales J; Díaz-Coto JF; Esteva-Spinetti MH; Guibert-Toledano M; Palazuelos FI; Keiserman MW; Lomonte AV; Mota LM; Pineda Villaseñor C; Alarcón GS;
Rheumatology (Oxford); 2008 Jul; 47(7):1097-9. PubMed ID: 18463144
[No Abstract] [Full Text] [Related]
9. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the treatment of rheumatoid arthritis.
Schuna AA
Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab (MabThera) as treatment of active rheumatoid arthritis].
El Fassi D; Nielsen CH; Bendtzen K
Ugeskr Laeger; 2006 Nov; 168(47):4079-81. PubMed ID: 17134602
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
[TBL] [Abstract][Full Text] [Related]
13. How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
van Vollenhoven RF
Ann Rheum Dis; 2009 Aug; 68(8):1237-9. PubMed ID: 19605741
[No Abstract] [Full Text] [Related]
14. Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis.
Risselada A; Tekstra J; Teng YK; Welsing PM; Breedveld F; van Laar JM; Bijlsma JW
Ann Rheum Dis; 2010 Oct; 69(10):1891-2. PubMed ID: 20444758
[No Abstract] [Full Text] [Related]
15. [The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].
Thurlings RM; Vos K; Gerlag DM; Tak PP
Ned Tijdschr Geneeskd; 2006 Jul; 150(30):1657-61. PubMed ID: 16922350
[TBL] [Abstract][Full Text] [Related]
16. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab.
Palanichamy A; Roll P; Theiss R; Dörner T; Tony HP
Arthritis Rheum; 2008 Dec; 58(12):3665-74. PubMed ID: 19035487
[TBL] [Abstract][Full Text] [Related]
17. Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab?
Boumans MJ; Vos K; Gerlag DM; Tak PP
Ann Rheum Dis; 2012 Mar; 71(3):472-3. PubMed ID: 21908451
[No Abstract] [Full Text] [Related]
18. Rituximab (Rituxan) for rheumatoid arthritis.
Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
[No Abstract] [Full Text] [Related]
19. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
[No Abstract] [Full Text] [Related]
20. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.
Edwards JC; Leandro MJ; Cambridge G
Rheum Dis Clin North Am; 2004 May; 30(2):393-403, viii. PubMed ID: 15172048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
